MOTS-c
Last reviewed 2026-10-30
Our read Opinion
FDA lists MOTS-c among withdrawn nominations, not as authorized for compounding. Trials of analogues should not be treated as proof for native MOTS-c; WADA 2026 S4.4.1 prohibits it.
- Type
- Research-only / unapproved
- Regulatory status
- Not FDA-approved; no verified marketing authorization
- Compounding status
- Off Category 2, review pending
- FDA-approved indications
- None
- Evidence level
- Animal studies mostly
- Routes studied
- —
- WADA
- Prohibited
- Developer
- —
Claims made by researchers, companies and users. Inclusion does not mean the claim is verified.
- —Claimed to support cellular energy and endurance
Mitochondrial-derived peptide linked to metabolic stress signaling and AMPK activation. Animal studies suggest effects on insulin sensitivity; endogenous biomarker associations do not establish treatment efficacy.
Not FDA-approved; marketing authorization elsewhere was not verified. FDA reports no identified human exposure data for drug products containing MOTS-c in its safety assessment.
Statuses change; check the linked primary source.
Momentum Opinion
Rising
0 news items in last 30 days
The mitochondrial biology is interesting, but longevity claims run ahead of treatment evidence. Human biomarker observations should not be confused with proven clinical benefit.
No news yet for this peptide.
Better cellular energy, endurance and 'mitochondrial aging' support.
Information only. Not medical advice. Listing a compound is not an endorsement or a recommendation to obtain or use it. Ratings and "Our Take" are editorial opinion. Full disclaimer.